Media & Resources
Engage with the leading edge of biopharmaceuticals

Press Release

Senator Mitch McConnell Visits Bexion Pharmaceuticals

Bexion Pharmaceuticals hosted Senator Mitch McConnell and his team at their Covington, KY headquarters on Friday, March 2 to provide an update on the progress of the Company’s anticancer therapy (BXQ-350).

“We are certainly honored to have Senator McConnell visit Bexion,” stated Dr. Ray Takigiku, Bexion’s co-founder and CEO. “Senator McConnell’s support of the SBIR/STTR program both at the Federal level and the matching program in Kentucky has helped Bexion progress toward our first in human clinical trials planned for early 2013.”

About BXQ-350

BXQ-350 is a novel nanovesicle composed of the human lysosomal protein Saposin C, and the lipid dioleoylphosphatidylserine (DOPS). This basic technology (dubbed “SapC-DOPS”) has shown preclinical efficacy against gliomas (GBM), as well as other refractory tumors including pancreatic cancer, and neuroblastomas. BXQ-350 has preferential affinity for tumors by targeting their phosphatidylserine-enriched membranes. With targeting, these nanovesicles also appear to selectively induce tumor apoptosis (cell-death).

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a privately owned company focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children’s Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as a tumor-targeting carrier for other pharmaceutical agents, such as oligonucleotides. For more information on Bexion and BXQ-350, visit www.bexionpharma.com.

Bexion Contact

Margaret M. van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065
mvangilse@bexionpharma.com